Founder Paul DiPerna helped build one of the best-known insulin pumps at Tandem Diabetes (TNDM). His next bet is that a simpler device, backed by broader pharmacy access, can win over people who have never used one.
Modular Medical, Inc. (NASDAQ: MODD) said on November 19 that it had secured agreements with all three of the largest U.S. pharmacy benefit managers for Pivot, its FDA-cleared tubeless insulin pump. The agreements build on a national contract announced in September and put the San Diego company in a better position for a planned full-scale launch in 2027. The milestone gives commercial weight to the $3 billion U.S. market opportunity Modular outlined in its October presentation. Its bet is not that people will abandon pumps they already like. It is that some people taking several insulin injections a day would switch if a pump were simpler to use and easier to get through their pharmacy benefit. The first problem is an engineering question. The second comes with considerably more paperwork.
The Big Three PBM Deals Open a Route to Patients
Pharmacy benefit managers, or PBMs, administer prescription benefits, process claims and help determine which products health plans cover. Drug Channels Institute identifies the three largest as CVS Caremark, part of CVS Health (NYSE: CVS); Express Scripts, part of The Cigna Group (NYSE: CI); and Optum Rx, part of UnitedHealth Group (NYSE: UNH). The institute estimates that the top three consistently process about 80% of U.S. equivalent prescription claims, a measure that puts prescriptions of different lengths on a comparable basis. Modular says the three networks collectively cover more than 182 million people. That is the reach of the networks, not the number of people whose plans now cover Pivot. Coverage for any individual still depends on the applicable health plan’s or plan sponsor’s formulary, the list of covered products, and benefit design, which determines what the patient pays and what requirements apply. The agreements matter because Modular now has a route through all three major PBMs as it works to expand distribution. They do not guarantee a particular copay or a paid prescription. Jeb Besser, Modular Medical’s chief executive officer, said the contracts “establish an important foundation for broader patient access through standard pharmacy benefits” and support the rollout over the coming year. Mark Brady, the company’s director of managed markets, emphasized the patient-level test: Modular believes the agreements can reduce traditional coverage barriers and help more people move from multiple daily injections to pump therapy. Besser’s point is about distribution. Brady’s is about whether that distribution makes Pivot accessible and affordable enough for patients to switch.
Where the $3 Billion Opportunity Comes From
Modular calls its target customers “almost pumpers.” Its October presentation starts with an estimated 1.2 million people with type 1 diabetes and 1.6 million with type 2 diabetes in the U.S. who use multiple daily injections. Management assumes that 28% of the first group and 25% of the second fit its target profile. That yields roughly 736,000 potential users, split between an estimated $1.37 billion opportunity in type 1 diabetes and $1.63 billion in type 2. The model draws in part on a 2021 survey of healthcare professionals. It is management’s estimate of the addressable market, not a revenue forecast or a tally of covered patients. The adoption gap explains why type 2 accounts for the larger share of the model. Modular’s deck puts pump use at roughly one in three Americans with type 1 diabetes, versus about 8% of insulin-dependent Americans with type 2 diabetes. It also estimates that continuous glucose monitors, which track glucose throughout the day, have about four times as many U.S. users as insulin pumps. Wearing a glucose monitor is not the same as handing insulin delivery over to a device. Still, the gap helps explain why Modular is looking for its next customers among people using injections, not just among people shopping for a replacement pump.
Paul DiPerna’s Second Act: A Pump for People Who Haven’t Bought One
Modular founder and president Paul DiPerna founded Tandem Diabetes Care (NASDAQ: TNDM) and was the original designer and lead developer of its t:slim insulin pump. At Tandem, he helped build a pump for people who wanted more from the technology. At Modular, he is betting that a different group would rather have less to manage. Pivot pairs a reusable pump with a disposable three-day cartridge and a 3-milliliter insulin reservoir. It delivers a programmed background dose, and users can initiate a bolus, or an additional dose, with a button on the device. It does not require a separate controller, and users do not have to recharge the pump or replace its battery. Modular also offers a virtual walkthrough so prospective users can see how the patch is prepared and applied before formal training. Modular is not alone in pursuing this market. Insulet (NASDAQ: PODD), the maker of Omnipod, also sees insulin-requiring type 2 diabetes as an opportunity. Modular’s competitive test is whether Pivot’s simpler design and pharmacy access together persuade people who have passed on pump therapy to give it a try.
Five Markets Will Show Whether Coverage Turns Into Sales
Pivot received its initial FDA clearance in April 2026, and Modular began initial U.S. shipments in June. A phased rollout across five U.S. markets began in October, with a full-scale launch anticipated in 2027. According to the October deck, those five markets account for about 15% of new U.S. pump starts in the claims data Modular analyzed. They give the company a chance to see where prescriptions get held up, what patients pay and whether first-time users return for replacement cartridges. The balance sheet makes those early results important. Modular reported $5.1 million in cash and equivalents at September 30 and used $12.3 million in operating cash over the preceding six months. It had not recognized revenue from its initial low-volume Pivot shipments and disclosed substantial doubt about its ability to continue as a going concern. Additional equity financing could dilute shareholders, and the broader rollout will depend in part on how much capital the company can raise. For many following MODD, the most revealing numbers from here will be how many plans add Pivot, how many prescriptions become paid fills and how often patients reorder supplies. The bullish case is stronger because Modular has secured agreements with the three largest pharmacy gatekeepers before its planned national expansion. The five-market rollout will show whether a simpler pump and a better route to coverage are enough to win over people who have stuck with injections.
The Sources
- Modular Medical, November 19 announcement of agreements with all three of the largest U.S. PBMs
- Modular Medical, October 2026 corporate presentation, including the $3 billion market model, adoption estimates and founder biography
- Modular Medical, announcement of its initial national PBM agreement
- Drug Channels Institute, The Top Pharmacy Benefit Managers of 2025
- Federal Trade Commission, interim staff report on pharmacy benefit managers
- SEC, Modular Medical March 3, 2026 filing exhibit, including Paul DiPerna’s background
- Modular Medical, Pivot Insulin Delivery System product information and walkthrough
- FDA, September 2026 Pivot 510(k) clearance letter and decision summary
- SEC, Insulet 2025 Form 10-K, including its discussion of insulin-requiring type 2 diabetes
- SEC, Modular Medical Form 10-Q for the quarter ended June 30, 2026
- Modular Medical, November 17 company release on Pivot’s phased rollout and commercial update
- SEC, Modular Medical Form 10-Q for the quarter ended September 30, 2026
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.

Dow Advances While Chip Stocks Hit the Snooze Button – Monday, Aug. 24 -( $AMWL $BTC $GLD $EPRX $HPP $LPL $MODD $SMWB $YSG Rise! )-